 SEATTLE, March 22, 2021 PRNewswire -- CTI BioPharma Corp. Nasdaq: CTIC, today announced that Clinical Cancer Research, a journal of the American Association for Cancer Research, has published results from a Phase 1 study led by Joseph Pidala, MD, PhD Moffitt Cancer Center, and Brian C. Betts, MD Masonic Cancer Center at the University of Minnesota, evaluating pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, for the prevention of acute graft-versus-host disease GVHD. 